Teva debuts 1% sodium hyaluronateTeva's 1% sodium hyaluronate is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy. Lupin gets FDA nod for 2 genericsLupin has received approval for cinacalcet tablets and phenylephrine and ketorolac intraocular solution, which had a market value of roughly $1.5 billion and $42.8 million, respectively. Shining stars: Luminaries in the generics industry Drug Store News is shedding some light on the luminaries of the generics industry who are committed to making cost savings possible, while simultaneously helping to keep patients healthy. MSN Labs’ generic Zytiga receives FDA approval Generic Zytiga has been approved for the treatment of prostate cancer when used with steroid medication. Zydus Cadila gets FDA OK for generic Cytotec Zydus Cadila's Food and Drug Administration approved misoprostol tablets are used to prevent stomach ulcers in patients taking pain medications. Alembic gets FDA green light for 2 generics Clonazepam had a market value of about $20 million and Febuxostat had a market value of roughly $578 million for the 12 months ended December 2018. Amneal announces restructuring and costs savings plan Amneal’s restructuring and cost savings plan is expected to reduce costs by approximately $50 million annually. Pfizer gets FDA nod for biosimilar Avastin Pfizer's Zirabev is a biosimilar of Avastin, which is indicated for the treatment of five types of cancer. Glenmark gets FDA nod for generic Ranexa Ranexa ER tablets, 500 mg and 1,000 mg, had a market value of roughly $929 million for the 12 months ended May 2019. Lupin launches generic Gleevec Imatinib mesylate tablets had a market value of about $548 million, according to IQVIA May 2019 data. First Previous 183 184 185 186 187 Next Last
